In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Applied Imaging Corp.

Division of Danaher Corp.
www.aicorp.com

Latest From Applied Imaging Corp.

BD's Progress in Molecular Markers

Having already collaborated with Millennium Pharmaceuticals to find marker candidates for its molecular oncology program, BD is now tapping TriPath Imaging to help build an imaging system to analyze the markers. Its strategy of relying on partners means it has to give up some profits, but BD is confident that the results will yield a value high enough to make the program economically feasible. It's a model that other companies are likely to emulate as they move into molecular diagnostics.
BioPharmaceutical Medical Device

Vysis Preps For Prime Time

Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
BioPharmaceutical Medical Device

A FISH on the Line

Vysis Inc., which is attempting to penetrate the market with its FISH DNA probe technology, got a boost in May when it announced a collaboration with Genentech Inc. to couple the FISH breast cancer test with Genentech's drug, Herceptin. Vysis hopes the deal will showcase FISH technology and attract other drug developers as partners. Genentech, meanwhile, needs such a test to better screen one class of patients to determine their suitability for treatment with Herceptin, in light of controversy over how accurate the existing IHC diagnostic test is in determining their Her2 status.
Medical Device Platform Technologies

Emerging Approaches to Cancer Diagnostics

Genetics and other technological advances are changing cancer diagnostics research, much as they have other areas of medicine, but researchers face, among other hurdles, information overload.
Medical Device Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Perceptive Scientific Instruments
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Danaher Corp.
  • Senior Management
  • Robin C Stracey, Pres. & CEO
    Terry Griffin, Corp. VP, CFO
    Daniel Bowman, VP, Worldwide Sales & Mktg.
  • Contact Info
  • Applied Imaging Corp.
    Phone: (408) 719-6400
    120 Baytech Dr.
    San Jose, CA 95134
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register